Month: January 2021

Vancouver, January 27, 2020 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) announces results for the fiscal year ending October 31, 2020. All references to dollar amounts in this release are in Canadian dollars.Highlights During and After the Quarter      During the three months ended October 31, 2020 the Company:Completed a non-brokered private placement for proceeds of $3,520,000 by issuing 32,000,000 units at a price of $0.11 per unit.  Each unit consists of one common share, and one common share purchase warrant exercisable into one common share at an exercise price of $0.20 expiring August 7, 2024.Received information that the Bucharest Court of Appeal published a ruling dismissing the appeal against the Agenţia Natională Pentru Resurse Minerale (“NAMR”)...

VANCOUVER, British Columbia, Jan. 27, 2021 (GLOBE NEWSWIRE) — A.I.S. Resources Limited (TSX-V – AIS, OTCQB: AISSF) (the “Company” or “AIS”) announces it has closed its non-brokered private placement of 15,625,000 units (“Units“) at a price of $0.08 per unit for gross proceeds of $1,250,000 (the “Private Placement“). The proceeds will be used for exploration of the Company’s gold projects and general working capital purposes.Each Unit consists of one common share and one transferrable share purchase warrant. Each warrant will entitle the holder thereof to purchase one additional common share for a period of 24 months from the closing date of the offering at a price of $0.12 per common share. Insiders participated in the aggregate amount of $159,040 for 1,988,000 units. The Company shall pay finders fees totaling...

NEW YORK, Jan. 27, 2021 (GLOBE NEWSWIRE) — Elmira Savings Bank (NASDAQ:ESBK)HighlightsNet income was $1,284,000 and $4,159,000 for the three and twelve months ended December 31, 2020 compared to $940,000 and $3,486,000 for the same periods in 2019.Diluted earnings per share were $.37 per share and $1.19 per share for the three and twelve months ended December 31, 2020 compared to $.27 per share and $1.00 per share for the same periods in 2019.  Return on average assets was .78% and .64% for the three and twelve months ended December 31, 2020 compared to .61% and .57% for the three and twelve months ended December 31, 2019.Return on average equity was 8.40% and 6.94% for the three and twelve months ended December 31, 2020 compared to 6.33% and 5.93% for the same periods in 2019.“We are pleased to report an increase in earnings...

IRVINE, Californie, 27 janv. 2021 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq : CLPT), une société mondiale de plateforme de traitement permettant la navigation et l’acheminement au cerveau, a annoncé aujourd’hui que le Docteur Ernesto Salegio rejoindrait la société le 1er mars 2021 en tant que vice-président, chef de segment de la recherche translationnelle et préclinique au sein de l’équipe chargée de la biologie et de la distribution des médicaments. Le Dr Salegio apporte plus de 19 ans d’expérience dans le domaine des neurosciences translationnelles avec une expertise préclinique directe du système nerveux central (SNC) en matière d’administration des thérapies au cerveau et à la moelle épinière, ainsi que plus de 16 ans d’expérience de thérapie génique avec les vecteurs viraux adéno-associés...

IRVINE, Kalifornien, Jan. 27, 2021 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq: CLPT), ein weltweit tätiges Unternehmen, das Neuronavigationssysteme für die Durchführung von Eingriffen am Gehirn entwickelt, hat heute bekanntgegeben, dass Ernesto Salegio, PhD, am 1. März 2021 als Vice President, Segment Leader Translational and Pre-Clinical Research Teil des Biologics and Drug Delivery-Teams von ClearPoint wird. Dr. Salegio verfügt über mehr als 19 Jahre Erfahrung in der translationalen Neurowissenschaft mit direkter präklinischer Fachkompetenz im Bereich des zentralen Nervensystems (ZNS) und der Verabreichung von Therapeutika in Gehirn und Rückenmark, einschließlich über 16 Jahren Erfahrung in der Gentherapie mit Adeno-assoziierten viralen Vektoren (AAV).ClearPoint Neuro hat sein Team für Biologics und Drug Delivery 2020 gegründet,...

MENLO PARK, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its fourth quarter 2020 financial results on Wednesday, February 10, 2021, at 4:30pm Eastern Time.The call will be webcast and may be accessed at Pacific Biosciences’ website at: https://investor.pacificbiosciences.com/.Date: February 10, 2021Time: 4:30pm ETListen via Internet: https://investor.pacificbiosciences.com/Toll-free: 888.366.7247International: 707.287.9330Conference ID: 8096067Replay: https://investor.pacificbiosciences.comAbout Pacific BiosciencesPacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing...

GRAND HAVEN, Mich., Jan. 27, 2021 (GLOBE NEWSWIRE) — Access-Power & Co., Inc., (“ACCR or the Company”), a Grand Haven based diversified holding Company is pleased to announce the Company has retained Steve Mills as our Securities Counsel. “We are very excited about his joining our team,” commented Patrick J. Jensen, Director of ACCR.“He will help us and file the Attorney Letter with OTC Markets,” stated Patrick, Director of ACCR. His profile with OTC Markets can be viewed here.https://www.otcmarkets.com/learn/service-providers/8856“Steve comes highly recommended. We have enjoyed getting to know each other,” stated Patrick, “He will represent us in our re-application to up list to OTC Current Information next week with OTC Markets.His complete profile may be viewed here.https://www.linkedin.com/in/steve-millshttps://www.stevemillslaw.comIn...

NEW YORK, Jan. 27, 2021 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that an analyst note commenting on the listing of Intercept’s product on the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) website reached a conclusion regarding the status of a newly identified safety signal (NISS) for Ocaliva® (obeticholic acid) that the Company believes is incorrect.The FDA provides quarterly information on newly identified safety signals. The Company does not believe that the absence of a listed medicine that was in one quarterly update in a subsequent quarter necessarily indicates that the FDA has completed its evaluation of the...

TORONTO, Jan. 27, 2021 (GLOBE NEWSWIRE) — (TSX: DGS, DGS.PR.A) Investors and investment advisors are invited to listen to an update presentation on Dividend Growth Split Corp. (“DGS”) hosted by Chief Investment Officer, Laura Lau of Brompton Funds. Laura provides an update on the fund’s dividend growth portfolio and the market outlook. Brompton believes that Canadian stocks are undervalued and historically dividend growers have outperformed the broader market with lower volatility. The presentation recorded on January 25, 2021 has been posted to the Brompton Funds website at the following link:Dividend Growth Split Corp. UpdateDGS invests in a portfolio consisting primarily of equity securities of large capitalization Canadian dividend growth companies. In addition, DGS may hold up to 20% of the total assets of the portfolio in...

DEERFIELD, Ill., Jan. 27, 2021 (GLOBE NEWSWIRE) — BAB, Inc. (OTCQB: BABB), today announced that its Board of Directors has declared a quarterly distribution of one cent ($0.01) per share, payable on February 24, 2021 to shareholders of record as of February 10, 2021.